Usefulness and Safety of Transcatheter Ablation of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy

Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis

“…Of these, 177 were excluded as they were either duplicates or deemed unsuitable for the purpose of the meta-analysis (editorials, letters, reviews or case reports). The remaining 32 studies were carefully screened and after analysis of their abstracts and/or full-text only [14][15][16][17][18][19][20][21][22][23][24][25][26][27] (one was a conference abstract 22 ) were considered adequate for inclusion in the systematic review (figure 1). Of these, only six studies, 16 19 22-25 provided enough details to be included in the meta-analysis.…”

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

“…Amiodaron wydaje się bezpiecznym lekiem antyarytmicznym u pacjentów z kardiomiopatią przerostową i AF [879], a eksperci są zdania, że dizopiramid może być korzystny u pacjentów z zawężeniem drogi odpływu. Ablacja AF skutecznie ogranicza objawowe nawroty AF [880][881][882][883][884]. Chirurgiczne leczenie AF może być właściwe u pacjentów z kardiomiopatią przerostową, którzy są poddawani operacji (np.…”

Outcomes of long-standing persistent atrial fibrillation ablation: A systematic review

“…Gaita et al 18 reported one of the poorest single procedure, drug free success rates of only 15% in their long-standing persistent sub-group; however, all patients suffered from hypertrophic cardiomyopathy and their results were therefore excluded from summary statistics. Similarly, the data of Siedl et al 20 have also been excluded as their technique utilized two paired but chronologically-separate procedures of linear ablation that is not consistent with contemporary ablation approaches.…”